文献速递胃肠外科围术期管理与 ERAS

晚期复发不可切除腹膜假黏液瘤肠移植的中期随访首报

First Report With Medium-term Follow-up of Intestinal Transplantation for Advanced and Recurrent Nonresectable Pseudomyxoma Peritonei.
PubMed 文献 · Ann Surg · 2022-12-05

该单中心报告2013至2022年15例营养衰竭且不适合进一步CRS的复发腹膜假黏液瘤患者,行根治性减瘤联合肠移植。8例孤立小肠移植、7例改良多脏器移植,7例加行腹壁移植。1年与5年生存率分别为79%和55%,91%随访超6个月者出现疾病进展/复发。

要点

  • 对不适合进一步CRS的复发PMP,肠/多脏器移植是可选术式。
  • 1年与5年生存率分别为79%和55%,90天内2例手术相关死亡。
  • 随访超6个月者91%出现疾病进展/复发,需权衡获益与风险。

核心结论

  • 肠/多脏器移植为常规手术无选择的PMP患者提供更根治的外科途径。
  • 该复杂手术需腹膜恶性肿瘤团队与移植团队联合完成。

研究设计与样本

  • 单中心2013至2022年纳入15例营养衰竭且不适合进一步CRS的PMP患者。
  • 行根治性减瘤联合个体化肠移植,8例孤立小肠移植、7例改良多脏器移植。
  • 7例因腹壁肿瘤显著受累加行全层带血管腹壁移植。

主要发现

  • 15例中2例于90天内死于手术相关并发症。
  • 1年与5年实际生存率分别为79%和55%。
  • 多数患者移植后生活质量显著改善。
  • 随访超过6个月的患者中91%检出疾病进展/复发。

临床怎么用

  • 仅对营养衰竭且无常规手术选项的复发PMP考虑肠/多脏器移植。
  • 术前需腹膜恶性肿瘤与移植团队联合评估并个体化制定移植范围。
  • 术后需密切监测疾病进展/复发,因随访超6个月者91%出现进展/复发。

局限性

  • 单中心小样本(15例)经验,随访时间有限。
  • 非对照设计,无法与传统手术或其他治疗直接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report our experience with the combination of radical surgical excision and intestinal transplantation in patients with recurrent pseudomyxoma peritonei (PMP) not amenable to further cytoreductive surgery (CRS). BACKGROUND: CRS and heated intraoperative peritoneal chemotherapy are effective treatments for many patients with PMP. In patients with extensive small bowel involvement or nonresectable recurrence, disease progression results in small bowel obstruction, nutritional failure, and fistulation, with resulting abdominal wall failure. METHODS: Between 2013 and 2022, patients with PMP who had a nutritional failure and were not suitable for further CRS underwent radical debulking and intestinal transplantation at our centre. RESULTS: Fifteen patients underwent radical exenteration of affected intra-abdominal organs and transplantation adapted according to the individual case. Eight patients had isolated small bowel transplantation and 7 patients underwent modified multivisceral transplantation. In addition, in 7 patients with significant abdominal wall tumor involvement, a full-thickness vascularized abdominal wall transplant was performed. Two of the 15 patients died within 90 days due to surgically related complications. Actuarial 1-year and 5-year patient survivals were 79% and 55%, respectively. The majority of the patients had significant improvement in quality of life after transplantation. Progression/recurrence of disease was detected in 91% of patients followed up for more than 6 months. CONCLUSION: Intestinal/multivisceral transplantation enables a more radical approach to the management of PMP than can be achieved with conventional surgical methods and is suitable for patients for whom there is no conventional surgical option. This complex surgical intervention requires the combined skills of both peritoneal malignancy and transplant teams.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Reddy S, Punjala SR, Allan P, et al. First Report With Medium-term Follow-up of Intestinal Transplantation for Advanced and Recurrent Nonresectable Pseudomyxoma Peritonei. Ann Surg. 2022. PMID: 36468404. doi:10.1097/SLA.0000000000005769

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。